Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714544 · ClinicalTrials.gov registry record · Phase 4
Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
A Phase 4 study of Psoriasis, sponsored by Promius Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT01714544 is a Phase 4 study of Psoriasis that has completed, run by Promius Pharma. The registered enrollment target is 60 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (88% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT01714544, a Phase 4 study of Psoriasis, has completed, sponsored by Promius Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether Cloderm Cream is effective for topical treatment of moderate psoriasis over 28 days.
Conditions Studied
Interventions
- DRUG Cloderm Cream
Study Locations (5)
Texas
- DermResearch, Inc. - Austin
- Research Across America - Dallas
Ohio
- Radiant Research, Inc. - Cincinnati
Oregon
- Oregon Medical Research - Portland
Wisconsin
- Madison Skin and Research, Inc. - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01714544
The ClinicalTrials.gov registry entry for NCT01714544 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (88% lower). The listed sponsor is Promius Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Cloderm Cream is the first listed.
NCT01714544 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT01714544 about?
NCT01714544 is a clinical study titled "Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis". The purpose of this study is to determine whether Cloderm Cream is effective for topical treatment of moderate psoriasis over 28 days.
What is the current status of trial NCT01714544?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2012-10.
What conditions does trial NCT01714544 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01714544?
The interventions under investigation include: Cloderm Cream (DRUG).
Who is sponsoring clinical trial NCT01714544?
This trial is sponsored by Promius Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714544 being conducted?
This trial has 5 study locations across Ohio, Oregon, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.